Kura Oncology to Report Third Quarter 2017 Financial Results

On October 31, 2017 Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that it will report third quarter 2017 financial results after the close of U.S. financial markets on November 7, 2017 (Press release, Kura Oncology, OCT 31, 2017, View Source [SID1234521367]). Kura Oncology’s management will host a webcast and conference call at 4:30 p.m. EST/1:30 p.m. PST that day to discuss the financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 2685708. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 2685708.

Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial Markets

On October 31, 2017 Nektar Therapeutics (Nasdaq: NKTR) reported that it will announce its financial results for the third quarter ended September 30, 2017, on Tuesday, November 7, 2017, after the close of U.S.-based financial markets (Press release, Nektar Therapeutics, OCT 31, 2017, View Source [SID1234521369]). Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: View Source The web broadcast

[News Release] Announcement of FY2017 2nd Quarter Financial Results

Mitsubishi Tanabe Pharma releases FY2017 2nd quarter financial results(Press release, Mitsubishi Tanabe Pharma, OCT 31, 2017, View Source [SID1234521368]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017

On October 31, 2017 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, reported it will provide third quarter 2017 financial results and corporate highlights on Tuesday, November 7, 2017 after the market closes (Press release, Regulus, OCT 31, 2017, View Source [SID1234521372]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Regulus will host a conference call and webcast on November 7, 2017 at 5:00 p.m. Eastern Time to discuss third quarter 2017 financial results and corporate highlights. A live webcast of the call will be available online at www.regulusrx.com. To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 9297128. To access the telephone replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode 9297128. The webcast and telephone replay will be archived on the Company’s website following the call.

Cambrex to announce third quarter 2017 financial results on November 7, 2017

On October 31, 2017 Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reported that third quarter 2017 financial results will be released on Tuesday, November 7, 2017 before the market opens (Press release, Cambrex, OCT 31, 2017, View Source [SID1234521350]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call to discuss the financial results.

Third Quarter 2017 Earnings Conference Call

When: Tuesday, November 7, 2017 at 8:30 a.m. Eastern Time

Dial-in:

1-866-548-4713 for U.S.
1-323-794-2093 for International
Passcode: 1511082
Dial-in Replay:

1-888-203-1112 for U.S.
1-719-457-0820 for International
Passcode: 1511082
Available through Tuesday, November 14, 2017
Webcast: www.cambrex.com